Current Pharmaceutical Design
Title:Long Non-coding RNA and microRNAs as Novel Potential Biomarker and Therapeutic Target in the Treatment of Gastrointestinal Cancers
Volume: 24 Issue: 39
Author(s): Afsane Bahrami, Majid Khazaei and Amir Avan
Affiliation:
Export Options
About this article
Cite this article as:
Bahrami Afsane , Khazaei Majid and Avan Amir , Long Non-coding RNA and microRNAs as Novel Potential Biomarker and Therapeutic Target in the Treatment of Gastrointestinal Cancers, Current Pharmaceutical Design 2018; 24 (39) . https://dx.doi.org/10.2174/138161282439190314091937
DOI https://dx.doi.org/10.2174/138161282439190314091937 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anticancer Potential of Mefenamic Acid Derivatives with Platelet-Derived Growth Factor Inhibitory Property
Anti-Cancer Agents in Medicinal Chemistry Melatonin, a Potential Therapeutic Agent for Smooth Muscle-Related Pathological Conditions and Aging
Current Medicinal Chemistry Cardiovascular Effects of EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibodies
Cardiovascular & Hematological Agents in Medicinal Chemistry Mast Cells as Target in Cancer Therapy
Current Pharmaceutical Design Monoclonal Antibodies in Rare Acquired Thrombotic Disorders: The Paradigms of Paroxysmal Nocturnal Hemoglobinuria, Thrombotic Thrombocytopenic Purpura and Central Retinal Vein Occlusion
Current Vascular Pharmacology The Epidemiological, Mechanistic and Potential Clinical Role of Androgen Receptor (AR) in Urothelial Carcinoma
Current Drug Targets Netrin and DCC: Axon Guidance Regulators at the Intersection of Nervous System Development and Cancer
Current Drug Targets The Impact of DIDS-Induced Inhibition of Voltage-Dependent Anion Channels (VDAC) on Cellular Response of Lymphoblastoid Cells to Ionizing Radiation
Medicinal Chemistry FDG-PET/CT and SPECT/CT in Oncology
Current Medical Imaging Statins-Mediated Inhibition of Rho GTPases as a Potential Tool in Anti-Tumor Therapy
Mini-Reviews in Medicinal Chemistry Editorial [Hot Topic: Emerging Drugs in Gastrointestinal Tract (Executive Guest Editor: Predrag Sikiric)]
Current Pharmaceutical Design Development of an Efficient Screening System for HDAC Inhibitor Based on TCF Response Element
Anti-Cancer Agents in Medicinal Chemistry Editorial (Hot Topic: miRNA in the Pathogenesis and Therapy for Gastrointestinal and Hepatic Cancers)
Current Pharmaceutical Design Chondroitin Sulfate Glycosaminoglycans for CNS Homeostasis-Implications for Material Design
Current Medicinal Chemistry Polynuclear Ruthenium, Osmium and Gold Complexes. The Quest for Innovative Anticancer Chemotherapeutics
Current Topics in Medicinal Chemistry Reduced Lipocalin 2 Expression Contributes to Vincristine Resistance in Human Colon Cancer Cells
Recent Patents on Anti-Cancer Drug Discovery Alkaloids in the Nature: Pharmacological Applications in Clinical Practice of Berberine and Mate Tea
Current Topics in Medicinal Chemistry Clinical and Forensic Signs Related to Cocaine Abuse
Current Drug Abuse Reviews Cancer Targeted Therapy Strategy: The Pathologist’s Perspectives
Current Cancer Drug Targets Myricetin Induces Apoptosis in HepG2 Cells Through Akt/p70S6K/Bad Signaling and Mitochondrial Apoptotic Pathway
Anti-Cancer Agents in Medicinal Chemistry